Dianabol vs Pancragen
Well Studied vs Moderate Research
monitor Mechanism-based · 47% Both Dianabol and Pancragen affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Dianabol Pancragen
Weight 300.44 Da 576 Da
Half-life ~4-6 hours Not established
Chain — 4 amino acids
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Tetrapeptide bioregulator
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Pancragen
01 Corrects impaired glucose tolerance
02 Normalizes insulin levels
03 Normalizes C-peptide levels
04 Improves endocrine pancreatic function
05 Supports pancreatic cell differentiation
06 Regulates melatonin expression
07 Reduces metabolic syndrome incidence
08 Upregulates key pancreatic transcription factors
Dosing Protocols
Dianabol
20-50 mg/day / Split doses throughout the day
Pancragen
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 0.05 mg/kg Daily for 10 days
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Pancragen
Generally well-tolerated
Minimal side effects reported
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Active pancreatic emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Type 1 diabetes (consult physician)
Research Evidence
Dianabol Pancragen
Status Well Studied Moderate Research
References 5 studies 4 studies
Latest 2017 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.